The leading candidate for the repair of the central nervous system in multiple sclerosis failed in a Phase II study, highlighting the complexity ahead for a burgeoning pipeline of academic-led projects.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
19 August 2016
An RXRγ isoform-specific agonist was incorrectly identified as an RXRγ isoform-specific inhibitor. This has now been corrected online.
Rights and permissions
About this article
Cite this article
Mullard, A. Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis. Nat Rev Drug Discov 15, 519–521 (2016). https://doi.org/10.1038/nrd.2016.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.158
This article is cited by
-
Signaling mechanisms involved in the regulation of remyelination in multiple sclerosis: a mini review
Journal of Molecular Medicine (2023)
-
Stem cells: Stemming the tide
Nature (2016)
-
Erratum: Remyelination researchers regroup after proof-of-concept setback in multiple sclerosis
Nature Reviews Drug Discovery (2016)
